ADARx Pharmaceuticals develops a modality-agnostic RNA targeting platform that utilizes base editing of mRNA transcripts to create therapeutics for genetic, cardiometabolic, and central nervous system diseases. The company aims to provide effective treatments for intractable diseases by leveraging oligonucleotides for inhibition, degradation, and editing, along with advanced delivery technologies.

The startup operates a membership-based healthcare platform that delivers primary and urgent care services through a mobile application, enabling healthcare professionals to conduct home and workplace visits. By utilizing evidence-based medicine and a metrics-driven approach, the platform enhances patient health outcomes while ensuring compliance with healthcare standards.

Atea Pharmaceuticals is developing oral direct-acting antiviral therapies, specifically bemnifosbuvir and ruzasvir, for the treatment of hepatitis C virus (HCV) and COVID-19. The company targets the unmet medical need for effective antiviral treatments, as millions of HCV patients remain untreated despite the availability of therapies.

Clearside BioMedical specializes in the suprachoroidal administration of therapeutic products to treat retinal diseases, utilizing a proprietary method that allows drugs to be precisely delivered to the back of the eye. Their FDA-approved product, XIPERE®, targets macular edema associated with uveitis, addressing the need for effective treatments in this area.

HARM provides an AI-powered platform for individuals experiencing harm to quickly access immediate, trusted support. The system intelligently identifies the nature of the reported harm and routes users directly to appropriate, city-approved advocacy, legal, or housing resources. This streamlined process eliminates confusion while generating de-identified data insights to help municipal leaders optimize community support services.

InflammX Therapeutics develops Xiflam™, a once-daily oral small molecule that targets the pathologically open Connexin43 hemichannel to modulate the dysregulated NLRP3 inflammasome pathway. This approach addresses the unmet medical needs in diabetic macular edema, diabetic chronic kidney disease, and intermediate age-related macular degeneration, conditions currently lacking effective treatments.

Marius Pharmaceuticals develops KYZATREX, an oral testosterone undecanoate therapy absorbed primarily via the lymphatic system, designed to treat adult men with hypogonadism, a condition characterized by low testosterone levels. This therapy addresses the significant health impacts of testosterone deficiency, including fatigue, decreased libido, and increased risk of metabolic disorders, by restoring testosterone levels to the normal range in a majority of patients.

Mira develops mobile augmented reality platforms that integrate industrial wearables with software technologies to enhance operational efficiency in manufacturing environments. The company addresses the need for real-time data visualization and hands-free access to information, reducing downtime and improving worker productivity.

Nexus operates as a Layer 1 blockchain specifically engineered for high-performance, verifiable financial applications. Its architecture features a dual-core execution layer and the Nexus zkVM 3.0 to ensure low latency and verifiable computation. The platform integrates a native, verifiable CLOB (Central Limit Order Book) as an enshrined exchange for unified trading and settlement.

NOVA is a platform that connects creative professionals with job opportunities by allowing users to showcase their portfolios and post job listings tailored to specific project needs. It addresses the challenge of finding qualified talent quickly in the creative industry, having generated over $10 million for creatives and facilitated 17,000 job postings across more than 500 cities globally.

ON is an AI chat platform designed for enterprise use, integrating with e-commerce systems like Shopify to enhance customer interactions by providing real-time access to product and order information. This technology addresses the high volume of customer service inquiries, improving site conversions and customer satisfaction while reducing the workload for support agents.

Revi is a conversational marketing platform utilizing artificial intelligence to enhance customer engagement specifically for e-commerce businesses. It centralizes WhatsApp campaigns, behavioral data analysis, and team support into a single solution for managing the entire customer journey. The platform enables personalized campaign automation, real-time performance tracking, and intelligent customer relationship management to drive sales and recurring revenue.

Science is a clinical-stage technology company developing biohybrid neural interfaces and advanced neural recording electronics to address serious unmet medical needs in neuroscience. Their technologies aim to enhance neural communication and restore vision, facilitating new treatment possibilities for patients with neurological disorders.

The startup provides a platform that integrates Web3 functionalities within Telegram, enabling users to access decentralized applications and services directly through the messaging app. This solution addresses the challenge of user onboarding in Web3 by simplifying access to blockchain-based tools without requiring users to leave their familiar communication environment.

XSY is a DeFi protocol on Avalanche that lets USDC holders mint UTY and deposit it into one of two vaults. The yUTY vault auto‑compounds yield from funding perpetual contracts while hedging token price risk, and the xUTY vault accrues $XSY governance points for voting. Both vaults enforce a 7‑day unbonding period and use audited smart contracts and third‑party custody for security.